Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut. Show more

1 Enterprise Drive, Shelton, CT, 06484-4779, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

14.8M

52 Wk Range

$4.63 - $62.50

Previous Close

$5.84

Open

$5.76

Volume

109,394

Day Range

$5.76 - $7.09

Enterprise Value

11.15M

Cash

7.067M

Avg Qtr Burn

-2.387M

Insider Ownership

8.34%

Institutional Own.

7.89%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
INT230-6 Details Advanced Soft tissue sarcomas	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INT230-6 Details Neoadjuvant Triple-negative breast cancer	Phase 2 Re-initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
INT230-6 (Intratumoral Cytotoxic) Details Metastatic Or Refractory Advanced Solid Tumors	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.